Immunocore
Kimmtrak (tebentafusp), a soluble gp100 TCR-anti-CD3 bispecific for HLA-A02:01+ metastatic uveal melanoma, was reported in April 2026 to double the likelihood of being alive at five years — the first TCR-based bispecific approved.
- Country
- United Kingdom
- Ticker
- IMCR
Commercial
TCR bispecific (Kimmtrak)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| TCR therapy (T-cell receptor engineered T cells) | therapeutics-platforms | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.